Vaxess Awarded two NIH grants for stabilization of biospecimens

Vaxess Technologies, Inc., an innovative life sciences company developing a novel silk protein-based stabilization and delivery technology, was awarded two separate Phase I Small Business Innovation Research Grants (SBIR) from the National Institute of Health (NIH). 

Sponsoring institutes were the National Cancer Institute (NCI) and the National Institute for Environmental Health and Safety (NIEHS).

Funding totaling $448,416 is supporting the development of the technology, including method development for mass spectrometry analysis of various biomarkers in silk-stabilized blood and serum specimens. 

For more information, please refer to the two program descriptions:

NIEHS 

NCI